Skip to main content

Table 2 Comparison between patients with major bleeding or ICH, minor bleeding and no bleeding

From: Warfarin and fibrinolysis - a challenging combination: an observational cohort study

 

ICH or major bleeding, n = 7

Minor bleeding, n = 7

No bleeding, n = 22

Age (years)*

69 (63-72)

67 (61-78)

70 (62-79)

Sex; men

7 (100%)

5 (70%)

16 (73%)

Earlier fibrinolysis

0

3 (43%)

6 (27%)

Contraindication for fibrinolysis (other than warfarin)

1 (14%)

0

3 (18%)

Systolic BP*

126 (105-141)

127 (90-140)

122 (111-140)

Diastolic BP*

64 (61-92)

69 (60-81)

76 (70-90)

Fibrinolytic agent

   

   streptokinase

1 (14.3%)

0

5 (23%)

   tPA (alteplase)

1 (14.3%)

1 (14.3%)

1 (4.5%)

   reteplase

5 (71.4%)

5 (71.4%)

13 (59%)

   tenecteplase

0

1 (14.3%)

3 (13.5%)

Adjuvant medication

   

   aspirin

1 (14%)

3 (43%)

15 (68%)

   heparin

5 (71%)

5 (71%)

14 (64%)

UFH

3 (43%)

1 (14%)

2 (9%)

LMWH

2 (29%)

4 (57%)

12 (55%)

LMWH (i.v.+s.c.)

1 (14%)

2 (29%)

3 (14%)

LMWH only i.v.

1 (14%)

2 (29%)

6 (27%)

LMWH reduced dose s.c

0

0

3 (14%)

Laboratory parameters at hospital arrival

   

   thrombocytes (x109/l)*

168 (144-191)

205 (165-227)

161 (134-188)

   haemoglobin (g/l)*

153 (133-163)

145 (139-155)

136 (125-141)

Survival

   

   hospital discharge

5 (71%)

5 (71%)

16 (73%)

   30 days

5 (71%)

5 (71%)

14 (64%)

   1 year

5 (71%)

4 (57%)

13 (59%)

  1. * = median value (IQR), ICH = intracranial haemorrhage, BP = blood pressure, UFH = unfractionated heparin, LMWH = low molecular weight heparin, i.v. = intravenously, s.c. = subcutaneously.